9 September 2025 - Today, Pfizer Canada announced that its 20 valent pneumococcal conjugate vaccine, Prevnar 20, has been selected for the publicly funded pneumococcal immunisation program in the Canadian province of British Columbia . 

This program, launched in July 2025, includes routine immunisations of paediatric and older adult populations, as well as high-risk adult and paediatric populations.

Read Pfizer press release